In the fiscal year under review, consolidated net sales increased year-on-year, operating income increased, ordinary income, and profit attributable to owners of the parent decreased.

●Consolidated net sales totaled 198,380 million yen, an increase of 13,574 million yen (7.3%) year-on-year. Sales in the pharmaceuticals business underperformed, while the functional chemicals and safety systems businesses outperformed the previous fiscal year.
●Consolidated operating income totaled 21,505 million yen, an increase of 454 million yen (2.2%) year-on-year, outperforming the previous fiscal year in the pharmaceuticals and safety systems businesses, while underperforming in the functional chemicals industry.
●Consolidated ordinary income totaled 23,025 million yen, a decrease of 128 million yen (0.6%) year-on-year.
●Profit attributable to owners of parent was 14,984 million yen, a decrease of 2,196 million yen (12.8%) year-on-year, owing to recognition of an impairment loss on property, plant, and equipment.

(millions yen)	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03	2024/03
Net sales	161,861	162,922	159,117	167,888	172,639	175,123	173,381	184,805	198,380	201,791
Operating income	22,301	21,713	19,646	22,615	19,939	17,485	15,194	21,050	21,505	7,337
Ordinary income	25,162	21,016	19,947	22,480	21,608	18,026	16,538	23,154	23,025	12,562
Profit attributable to owners of parent	15,653	17,291	15,635	15,488	14,851	12,815	12,574	17,181	14,984	4,113
Operating income to net sales ratio	13.8%	13.3%	12.3%	13.5%	11.6%	10.0%	8.8%	11.4%	10.8%	3.6%
ROE	8.9%	9.2%	8.2%	7.7%	7.0%	6.0%	5.8%	7.3%	6.0%	1.6%